14.06.2022 - 16.06.2022Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 09:00 - 17:00
Temas de la conferencia The momentum in anti-HER2 drug development is exploding:
Outcomes for HER2-expressing breast cancer are patients constantly improving; diagnostics, trial design and innovative drug design are at an all-time high; complementing the newly accessible HER2 'low' space and wider range of tumor indications; the last year has given us more progress in HER2-targeted therapies than ever before.
Organizador profesional (PCO) Hanson Wade
Observaciones Speakers: Cecile Geuijen Chief Scientific Officer and Vice President - Oncology, Merus, Shane Olwill Chief Development Officer, Senior Vice President and Head of Translational Science, Pieris Pharmaceuticals and more.
Cuota del Congreso Industry Pricing - Conference + Workshop Day - Standard Rate: USD 4097.0,
Industry Pricing - Conference Only - Standard Rate: USD 2899.0
Cantacto organizador 83 Great Titchfield Street W1W 6RH London United Kingdom